NCT04284280

Brief Summary

The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
170

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

February 15, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 25, 2020

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 11, 2025

Completed
Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

3.7 years

First QC Date

February 15, 2020

Last Update Submit

April 27, 2026

Conditions

Keywords

Premature Human MilkPasteurized Premature Human MilkHuman Milk Donor FortifierNeurodevelopmental followup

Outcome Measures

Primary Outcomes (3)

  • In-Hospital growth in extremely preterm infants

    Compare the in-hospital growth in extremely preterm infants between routine fortification vs selective fortifications groups

    Remaining length of NICU admission from the time of randomization (approximately 2 years from recruitment starts)

  • Necrotizing Enterocolitis (NEC)

    Compare the difference in the incidence of NEC among the two groups

    Remaining length of NICU admission from the time of randomization (approximately 2 years from recruitment starts)

  • Neurodevelopmental outcome

    Assess the difference (if any) in developmental outcome at two years between the two group using Bayley IV

    Assessment will happen at two years adjusted age ( approximately 4 years from the time recruitment starts)

Secondary Outcomes (1)

  • The difference in growth (if any) at two years

    Assessment will be completed at two years adjusted age ( approximately 4 years from the time recruitment starts)

Study Arms (2)

Early Routine Fortification

EXPERIMENTAL

Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)

Dietary Supplement: Routine vs Selective use of Human Milk Donor Fortifier

Selective Fortification

ACTIVE COMPARATOR

Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.

Dietary Supplement: Routine vs Selective use of Human Milk Donor Fortifier

Interventions

Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.

Early Routine FortificationSelective Fortification

Eligibility Criteria

Age0 Days - 6 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • All extremely preterm infants with gestational age less or equal to 27 weeks who are admitted to the NICU prior to day of life seven and the first enteral feeding

You may not qualify if:

  • Infants with severe congenital anomalies such as chromosomal trisomy, congenital heart disease, and abdominal wall defect

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Crouse Hospital

Syracuse, New York, 13210, United States

Location

MeSH Terms

Conditions

Enterocolitis, Necrotizing

Condition Hierarchy (Ancestors)

EnterocolitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Study Officials

  • Bouraa Bou Aram, MD

    Crouse Hospital

    PRINCIPAL INVESTIGATOR
  • Swati Murthy, MD

    Crouse Hospital

    PRINCIPAL INVESTIGATOR
  • Steven J Gross, MD

    Crouse Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Attending Physician, Neonatologist

Study Record Dates

First Submitted

February 15, 2020

First Posted

February 25, 2020

Study Start

February 15, 2020

Primary Completion

October 31, 2023

Study Completion

November 11, 2025

Last Updated

April 30, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations